A phase 1, single center, placebo-controlled, interventional study to evaluate the safety, tolerability, and pharmacokinetic profiles in healthy subjects compared to placebo
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs OLX-10010 (Primary) ; OLX-10010 (Primary)
- Indications Hypertrophic scars
- Focus Adverse reactions
- Sponsors OliX Pharmaceuticals
- 05 Jul 2018 New source identified and integrated (NCT03569267).
- 29 May 2018 According to an OliX Pharmaceuticals media release, company has received the Phase I clinical trial authorization (CTA) with OLX10010, from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK as of May 11, 2018.
- 23 May 2018 New trial record